Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Tasadenoturev active in DIPG1213
From little subclones grow mighty oaks1170
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes826
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC823
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials749
Ecological management of the microbiota in patients with cancer676
Current understanding and management of CAR T cell-associated toxicities648
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines562
Novel ICI–TKI combination improves HCC outcomes545
Gut microbiota in colorectal cancer development and therapy502
Hodgkin lymphoma: great progress with room for improvement485
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma479
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC469
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles464
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime451
Sacituzumab govitecan plus pembrolizumab improves outcomes446
A new standard of care for advanced-stage urothelial carcinoma424
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown382
Ponatinib superior to imatinib in Ph+ ALL341
Mortality is similar with active monitoring339
From ESMO 2022332
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence328
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC321
Belzutifan as a new option in pheochromocytomas and paragangliomas319
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials318
Sacituzumab tirumotecan improves OS in mTNBC313
Understanding and overcoming multidrug resistance in cancer311
Emerging trends in the global burden of colorectal cancer306
Minimal residual disease as a target for liquid biopsy in patients with solid tumours304
Humanized mouse models for immuno-oncology research303
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma302
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC291
Craniospinal irradiation improves leptomeningeal metastasis control289
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours274
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs260
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer247
Vebreltinib effective in MET-amplified NSCLC244
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease235
Improving outcomes in patients with oesophageal cancer229
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests227
Unresectable stage III non-small-cell lung cancer: state of the art and challenges207
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship207
Biomarkers for immunotherapy of hepatocellular carcinoma201
Spatial landscapes of cancers: insights and opportunities196
MicroRNAs in oncology: a translational perspective in the era of AI192
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response188
Approvals in 2022: overall survival, dose optimization, new approvals and beyond184
New CAPSTONE of SCLC therapy?181
SHINE a light: frontline ibrutinib for MCL178
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC164
Women with clinically node negative breast cancer can safely avoid axillary surgery160
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’156
Domvanalimab plus zimberelimab shows promise in upper-tract cancers154
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma152
Prospective comparisons support the use of navigational bronchoscopy138
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC136
DREAMseq of therapy for BRAF-mutant melanoma129
From ESMO 2023: advances in lung cancer128
Circulating tumour DNA — looking beyond the blood126
Mitigating acute chemotherapy-associated adverse events in patients with cancer124
Targeting chromosomal instability in patients with cancer124
Long-term outcomes following CAR T cell therapy: what we know so far124
Multiomics STEP up in correlative analysis of response to CAR T cells118
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM118
From the ESMO Congress 2023114
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas112
Sentinel lymph node biopsy improves surgical management of cervical cancer111
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL108
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma107
Newly approved cancer drugs in China — innovation and clinical benefit103
Author Correction: Innovative approaches for lung cancer screening and interception100
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress99
Claudin 18.2 as a novel therapeutic target99
Lung cancer in patients who have never smoked — an emerging disease94
Clinical implications of T cell exhaustion for cancer immunotherapy94
Enhancing immunotherapy with tumour-responsive nanomaterials93
Targeted biopsy reduces detection of clinically insignificant cancer90
T-DXd effective as second-line therapy in G/GEJ cancers88
Less-frequent surveillance is noninferior to annual mammography88
Second-line tarlatamab improves OS in SCLC88
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy87
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics84
0.14857792854309